Bausch & Lomb Technolas
This article was originally published in The Gray Sheet
Expanded indication for 217A excimer laser system - to treat hyperopia with or without astigmatism - is undergoing final labeling review by FDA, B&L notes Oct. 18. Firm also announces U.S. debut of its SofLens multi-focal contact lens. Cleared via 510(k) in May, the presbyopic lens will allow improved fit compared with B&L's Occasions multi-focal lenses, which provide near and far vision in different zones. Corporate revenues for the third quarter (ended Sept. 28) are $466.7 mil., up 11%, including a 13% advance in contact lens sales, B&L reports Oct. 17. Earnings of $9.4 mil. are off 59.6%, including $16.7 mil. in after-tax restructuring charges and write-offs...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.